The Heat Shock Protein 90-Targeting Drug Cisplatin Selectively Inhibits Steroid Receptor Activation

Marcus C. Rosenhagen, C. Söti, Ulrike Schmidt, Gabriela M. Wochnik, F. Ulrich Hartl, Florian Holsboer, Jason C. Young, Theo Rein

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Cisplatin is an antineoplastic drug that binds to DNA, thereby inhibiting cell division and tumor growth. Cisplatin may also disrupt the function of some proteins, including heat shock protein 90 (Hsp90). We report that cisplatin dose-dependently inhibited transcriptional activity of the androgen receptor and the glucocorticoid receptor (GR) in transient reporter assays. A truncated, hormone-independent GR was only partially inhibited at significantly higher doses of cisplatin. Cisplatin treatment of neuroblastoma cells led to an immediate inhibition of hormone binding by GR, followed by proteasome-dependent degradation of the receptor. Other Hsp90-regulated proteins, i.e. the phosphokinases raf-1, lck, and c-src, were not affected, indicating a specific functional interference of cisplatin with the steroid receptors GR and androgen receptor. Cisplatin did not elicit a stress response, in contrast to geldanamycin. Immunoprecipitation revealed that cisplatin disrupts binding of GR to Hsp90. Moreover, cisplatin-treated Hsp90 was unable to associate with untreated ligand binding domain of GR. Reticulocyte lysate was able to restore hormone binding of GR in vitro, but not when the lysate was pretreated with geldanamycin. Our data reveal that cisplatin influences steroid receptors also independently of its DNA-mediated effects and, thus, suggest a novel modes of action for this cytostatic drug.

Original languageEnglish
Pages (from-to)1991-2001
Number of pages11
JournalMolecular Endocrinology
Volume17
Issue number10
DOIs
Publication statusPublished - Oct 1 2003

Fingerprint

HSP90 Heat-Shock Proteins
Steroid Receptors
Protein Transport
Cisplatin
Glucocorticoid Receptors
Pharmaceutical Preparations
Androgen Receptors
Hormones
Reticulocytes
DNA
Cytostatic Agents
Proteasome Endopeptidase Complex
Neuroblastoma
Immunoprecipitation
Cell Division
Antineoplastic Agents
Protein Kinases
Ligands

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology, Diabetes and Metabolism

Cite this

Rosenhagen, M. C., Söti, C., Schmidt, U., Wochnik, G. M., Hartl, F. U., Holsboer, F., ... Rein, T. (2003). The Heat Shock Protein 90-Targeting Drug Cisplatin Selectively Inhibits Steroid Receptor Activation. Molecular Endocrinology, 17(10), 1991-2001. https://doi.org/10.1210/me.2003-0141

The Heat Shock Protein 90-Targeting Drug Cisplatin Selectively Inhibits Steroid Receptor Activation. / Rosenhagen, Marcus C.; Söti, C.; Schmidt, Ulrike; Wochnik, Gabriela M.; Hartl, F. Ulrich; Holsboer, Florian; Young, Jason C.; Rein, Theo.

In: Molecular Endocrinology, Vol. 17, No. 10, 01.10.2003, p. 1991-2001.

Research output: Contribution to journalArticle

Rosenhagen, MC, Söti, C, Schmidt, U, Wochnik, GM, Hartl, FU, Holsboer, F, Young, JC & Rein, T 2003, 'The Heat Shock Protein 90-Targeting Drug Cisplatin Selectively Inhibits Steroid Receptor Activation', Molecular Endocrinology, vol. 17, no. 10, pp. 1991-2001. https://doi.org/10.1210/me.2003-0141
Rosenhagen, Marcus C. ; Söti, C. ; Schmidt, Ulrike ; Wochnik, Gabriela M. ; Hartl, F. Ulrich ; Holsboer, Florian ; Young, Jason C. ; Rein, Theo. / The Heat Shock Protein 90-Targeting Drug Cisplatin Selectively Inhibits Steroid Receptor Activation. In: Molecular Endocrinology. 2003 ; Vol. 17, No. 10. pp. 1991-2001.
@article{7774aad98ab64677a95283cef7f640d9,
title = "The Heat Shock Protein 90-Targeting Drug Cisplatin Selectively Inhibits Steroid Receptor Activation",
abstract = "Cisplatin is an antineoplastic drug that binds to DNA, thereby inhibiting cell division and tumor growth. Cisplatin may also disrupt the function of some proteins, including heat shock protein 90 (Hsp90). We report that cisplatin dose-dependently inhibited transcriptional activity of the androgen receptor and the glucocorticoid receptor (GR) in transient reporter assays. A truncated, hormone-independent GR was only partially inhibited at significantly higher doses of cisplatin. Cisplatin treatment of neuroblastoma cells led to an immediate inhibition of hormone binding by GR, followed by proteasome-dependent degradation of the receptor. Other Hsp90-regulated proteins, i.e. the phosphokinases raf-1, lck, and c-src, were not affected, indicating a specific functional interference of cisplatin with the steroid receptors GR and androgen receptor. Cisplatin did not elicit a stress response, in contrast to geldanamycin. Immunoprecipitation revealed that cisplatin disrupts binding of GR to Hsp90. Moreover, cisplatin-treated Hsp90 was unable to associate with untreated ligand binding domain of GR. Reticulocyte lysate was able to restore hormone binding of GR in vitro, but not when the lysate was pretreated with geldanamycin. Our data reveal that cisplatin influences steroid receptors also independently of its DNA-mediated effects and, thus, suggest a novel modes of action for this cytostatic drug.",
author = "Rosenhagen, {Marcus C.} and C. S{\"o}ti and Ulrike Schmidt and Wochnik, {Gabriela M.} and Hartl, {F. Ulrich} and Florian Holsboer and Young, {Jason C.} and Theo Rein",
year = "2003",
month = "10",
day = "1",
doi = "10.1210/me.2003-0141",
language = "English",
volume = "17",
pages = "1991--2001",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - The Heat Shock Protein 90-Targeting Drug Cisplatin Selectively Inhibits Steroid Receptor Activation

AU - Rosenhagen, Marcus C.

AU - Söti, C.

AU - Schmidt, Ulrike

AU - Wochnik, Gabriela M.

AU - Hartl, F. Ulrich

AU - Holsboer, Florian

AU - Young, Jason C.

AU - Rein, Theo

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Cisplatin is an antineoplastic drug that binds to DNA, thereby inhibiting cell division and tumor growth. Cisplatin may also disrupt the function of some proteins, including heat shock protein 90 (Hsp90). We report that cisplatin dose-dependently inhibited transcriptional activity of the androgen receptor and the glucocorticoid receptor (GR) in transient reporter assays. A truncated, hormone-independent GR was only partially inhibited at significantly higher doses of cisplatin. Cisplatin treatment of neuroblastoma cells led to an immediate inhibition of hormone binding by GR, followed by proteasome-dependent degradation of the receptor. Other Hsp90-regulated proteins, i.e. the phosphokinases raf-1, lck, and c-src, were not affected, indicating a specific functional interference of cisplatin with the steroid receptors GR and androgen receptor. Cisplatin did not elicit a stress response, in contrast to geldanamycin. Immunoprecipitation revealed that cisplatin disrupts binding of GR to Hsp90. Moreover, cisplatin-treated Hsp90 was unable to associate with untreated ligand binding domain of GR. Reticulocyte lysate was able to restore hormone binding of GR in vitro, but not when the lysate was pretreated with geldanamycin. Our data reveal that cisplatin influences steroid receptors also independently of its DNA-mediated effects and, thus, suggest a novel modes of action for this cytostatic drug.

AB - Cisplatin is an antineoplastic drug that binds to DNA, thereby inhibiting cell division and tumor growth. Cisplatin may also disrupt the function of some proteins, including heat shock protein 90 (Hsp90). We report that cisplatin dose-dependently inhibited transcriptional activity of the androgen receptor and the glucocorticoid receptor (GR) in transient reporter assays. A truncated, hormone-independent GR was only partially inhibited at significantly higher doses of cisplatin. Cisplatin treatment of neuroblastoma cells led to an immediate inhibition of hormone binding by GR, followed by proteasome-dependent degradation of the receptor. Other Hsp90-regulated proteins, i.e. the phosphokinases raf-1, lck, and c-src, were not affected, indicating a specific functional interference of cisplatin with the steroid receptors GR and androgen receptor. Cisplatin did not elicit a stress response, in contrast to geldanamycin. Immunoprecipitation revealed that cisplatin disrupts binding of GR to Hsp90. Moreover, cisplatin-treated Hsp90 was unable to associate with untreated ligand binding domain of GR. Reticulocyte lysate was able to restore hormone binding of GR in vitro, but not when the lysate was pretreated with geldanamycin. Our data reveal that cisplatin influences steroid receptors also independently of its DNA-mediated effects and, thus, suggest a novel modes of action for this cytostatic drug.

UR - http://www.scopus.com/inward/record.url?scp=10744220096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744220096&partnerID=8YFLogxK

U2 - 10.1210/me.2003-0141

DO - 10.1210/me.2003-0141

M3 - Article

C2 - 12869591

AN - SCOPUS:10744220096

VL - 17

SP - 1991

EP - 2001

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 10

ER -